<DOC>
	<DOC>NCT00157274</DOC>
	<brief_summary>The investigators designed a compassionate basis phase II study for refractory/relapsed mycosis fungoides/Sezary syndrome consisting of alemtuzumab (Campath) for primary evaluation of overall response and time to relapse. Other goals to consider are toxicity and time to new therapy.</brief_summary>
	<brief_title>Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome</brief_title>
	<detailed_description>- 20 relapsed or refractory advanced mycosis fungoides/Sezary syndrome patients are scheduled with gradually escalated doses (3 mg, 10 mg , and 30 mg) on sequential days during the first week, followed by 30 mg three times a week until 12 weeks. - Patients must have serology negative for human T-lymphotropic virus 1 (HTLV-1) and until three different regimens of chemotherapy. - Follow up for one year after last cycle of alemtuzumab.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Above 18 years old Eastern Cooperative Oncology Group (ECOG) 02 Liver and renal function test less than twice upper label No active infection Written informed consent One to three regimens of previous chemotherapies Abnormal renal or hepatic function Mycosis fungoides/Sezary syndrome in transformation HIV + HTLV1 + Pregnancy Lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Alemtuzumab</keyword>
	<keyword>Mycosis fungoides</keyword>
	<keyword>Sezary</keyword>
</DOC>